Everest Clinical Research (“Everest”), a leading full-service contract research organization (“CRO”) with deep expertise in clinical data management, biostatistics and statistical programming, announces it has acquired August Research (“August”). Everest is a portfolio company of Arlington Capital Partners (“Arlington”), a Washington, D.C. based private equity firm with extensive experience investing in regulated industries. August is a European CRO that provides Clinical Trial Services (“CTS”) and Pharmacovigilance (“PV”) services to a wide variety of pharmaceutical and biotechnology clients. The Company has worked on over 120 projects for Phase I-IV clinical trials across multiple therapeutic areas including cardiovascular, infectious disease, oncology and rare disease.
Read the full article: Everest Clinical Research Announces the Acquisition of August Research //